Novo Nordisk specializes in the research, development, and large-scale production of treatments for diabetes and obesity, notably insulin formulations and GLP-1 medicines like semaglutide marketed as Ozempic and Wegovy. Healthcare professionals and patients worldwide use its products to manage blood sugar and body weight. The company maintains a strong focus on chronic metabolic diseases with manufacturing and commercial operations spanning multiple continents.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 76,857 | — | 26,503 | 31.1% |
| Q3 2025 | 74,976 | — | 20,006 | -26.8% |
| Q4 2025 | 79,144 | — | 26,891 | -7.8% |
| Q1 2026 | 96,823 | — | 48,557 | 69.2% |
| Q2 2026 | 78,488 | 2.1% | 20,989 | -20.8% |
All markets — KeepWinning global stock screener
Other companies on NYSE: Southern Copper Corporation (SCCO), Welltower Inc. (WELL), Pfizer Inc. (PFE), Petróleo Brasileiro S.A. - Petrobras (PBR), NextEra Energy, Inc. (NEE), The TJX Companies, Inc. (TJX)